CG
ODT

Cutler Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Cutler Group’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,400
Closed -$2K – 6702
2021
Q2 		$2K Buy
+4,400
New +$15.1K ﹤0.01% 5162

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Cutler Group's ODT Position: Q4 2021 in Review

Cutler Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 13,800 shares — an estimated $32.6K sold.

Cutler Group first reported a position in ODT in Q3 2020 and held it in 5 quarters. The position peaked at $75K in Q3 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

  • Cutler Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 13,800 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $32.6K.
  • Cutler Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Cutler Group's Odonate Therapeutics, Inc. Common Stock position peaked at $75K in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.